Amir Fathi, MD, is program director of the Center for Leukemia at Massachusetts General Hospital; as well as an associate professor of medicine at Harvard Medical School
June 13th 2025
Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.
June 28th 2023
Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.